Company profile: Iambic Therapeutics
1.1 - Company Overview
Company description
- Provider of an AI-driven drug-discovery platform to optimize drug profiles and identify novel mechanisms of action, featuring NeuralPlexer (3D physics-based generative diffusion for protein-ligand structures), OrbNet (protein-ligand binding energetics), PropANE (multi-parameter lead selection), and Magnet (generative molecular design), plus a first-in-class CDK2/4 candidate for cyclin D- and E-driven cancers with reduced off-target toxicities.
Products and services
- AI-driven drug-discovery platform: Delivers algorithm-based drug discovery focusing on optimizing drug profiles and identifying novel mechanisms of action
- CDK2/4: First-in-class drug candidate targeting CDK2/4 to address cyclin D and E driven cancers with reduced off-target toxicities
- Magnet: Generative molecular design technology that explores chemical space for drug discovery, integrated with high-throughput chemistry platforms
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Iambic Therapeutics
IGM Biosciences
HQ: United States
Website
- Description: Provider of a proprietary, clinical-stage IgM antibody platform developing engineered IgM therapeutics for cancer, autoimmune and inflammatory diseases. Pipeline includes imvotamab (CD20xCD3) for autoimmune diseases, aplitabart (DR5) for colorectal cancer, and IGM-2644 (CD38xCD3) for autoimmune diseases, all in early trials. Also offers an expanded access program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IGM Biosciences company profile →
Sorrento Therapeutics
HQ: United States
Website
- Description: Provider of proprietary drug therapeutics under development to address unmet medical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sorrento Therapeutics company profile →
IONIQ Sciences
HQ: United States
Website
- Description: Provider of solutions for early detection of multiple cancers to improve survivability and reduce healthcare costs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IONIQ Sciences company profile →
Kronos Bio
HQ: United States
Website
- Description: Provider of oncology therapies that modulate historically undruggable cancer targets. Pipeline includes KB-0742, a CDK9 inhibitor in phase 1/2 for MYC-dependent tumors, and KB-9558 targeting the p300 KAT domain for multiple myeloma. Offers a Small Molecule Microarray screening platform for transcription factor binding assays and a discovery collaboration with Genentech.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kronos Bio company profile →
Hybrigenics
HQ: France
Website
- Description: Provider of bioinformatics platforms to identify, validate, and inhibit protein interactions to develop cancer therapeutics; a biopharmaceutical company focused on R&D of new targets and therapies against cancer, researching deubiquitinating enzymes (DUBs), and having stopped development of inecalcitol, a vitamin D receptor agonist.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hybrigenics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Iambic Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Iambic Therapeutics
2.2 - Growth funds investing in similar companies to Iambic Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Iambic Therapeutics
4.2 - Public trading comparable groups for Iambic Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →